Susan Hasty, Publisher
Table of Contents . . . November 21st, 2002
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Gene Therapy Weekly | Other Publications
Cancer Gene Therapy - Gene agent inhibits tumor growth through apoptosis
Urinary Disease - Ex vivo gene transfer may offer better option for treating urinary problems
Bladder Cancer - Low receptor levels impact adenovirus-based bladder cancer gene therapy
Colorectal Cancer - Cytokine gene therapy shows antitumor effect on small rectal cancers
Inflammatory Bowel Disease - Antisense oligonucleotides rebuff intestinal inflammation in ileitis model
Peripheral Vascular Disease - Growth factor beneficial for restoring vascular function in limbs
Bone Marrow Transplantation - Bone marrow Fas ligand transduction may improve engraftment
Cancer Gene Therapy - Genta reiterates company progress and timelines for Genasense
Drug Delivery - System to administer medications has several applications
Drug Development - Biopharmaceuticals manufacturing collaboration announced
Funding - Cell death research awarded NIH research grant
HIV/AIDS Therapy - Mutagenesis can augment antiviral immunotoxin efficacy
Immunology - Novel DNA molecules are potent, selective immunoregulators
Investment Banking - CytRx Corp. announces agreement with Sands Brothers
Non-Small Cell Lung Cancer - Manufacturing agreement signed for antisense drug
Non-Small Cell Lung Cancer - Phase III trial status for Affinitac announced
Pancreatic Cancer - Reengineered cancer cells control tumor activity via angiogenic inhibition
Pneumocystis Carinii - Interleukin-10 gene suppresses inflammation in opportunistic infection
Soft Tissue Sarcoma - Patient enrollment completed for phase I gene therapy clinical trial
Virology - Purdue corrals new Trojan horse to replace wayward genes in mice
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.